PF-08046032

PF-08046032 is a novel antibody-drug conjugate (ADC) developed for the treatment of advanced cancers, including lymphomas and solid tumors. It consists of a detuned-affinity anti-CD25 antibody linked to monomethyl auristatin E, a potent cytotoxic agent. The drug is engineered to selectively deplete regulatory T cells (Tregs) within the tumor microenvironment (TME), which express high levels of CD25, while sparing peripheral Tregs to reduce autoimmune toxicity risk. Preclinical studies have shown that PF-08046032 preferentially kills intratumoral Tregs and enhances antitumor immune responses, especially when combined with checkpoint inhibitors such as anti-PD1 antibodies. The drug is currently in Phase 1 clinical trials as both monotherapy and in combination with sasanlimab for patients with advanced or metastatic malignancies. Developed by Pfizer.